Salud Pallares-Rodriguez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.
Journal: Antimicrobial agents and chemotherapy
Published: March 27, 2026
Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310).
Journal: Antimicrobial agents and chemotherapy
Published: February 19, 2026
Emergence of New Delhi Metallo-β-Lactamase 14-Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands.
Journal: Emerging infectious diseases
Published: January 30, 2026
Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: October 21, 2025
Enterococcus thailandicus: Genomic evidence of a potential new player in enterococcal virulence and antimicrobial resistance.
Journal: New microbes and new infections
Published: September 09, 2025
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.
Journal: Antimicrobial agents and chemotherapy
Published: July 25, 2025
Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: May 27, 2025
In vivo evolution of resistance to novel β-lactam/β-lactamase inhibitor combinations through overproduction of the horizontally acquired extended-spectrum AmpC β-lactamase FOX-14 and porin disruption in Serratia marcescens.
Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Published: May 14, 2025
Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants.
Journal: Antimicrobial agents and chemotherapy
Published: April 22, 2025
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors.
Journal: Antimicrobial agents and chemotherapy
Published: January 10, 2025
Last Updated: 09/26/2026